EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes

Sivasubramanium V Bhavani, Chad Robichaux, Philip A Verhoef, Matthew M Churpek, Craig M Coopersmith

CHEST · 2024-03 · 165 (3) · 529-539

DOI: 10.1016/j.chest.2023.09.020 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2024-03. Verfasst von Sivasubramanium V Bhavani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University, Atlanta, GA; Emory Critical Care Center, Atlanta, GA. Electronic address: sbhava2@emory.edu. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Trajectories of bedside vital signs have been used to identify sepsis subphenotypes with distinct outcomes and treatment responses. The objective of this study was to validate the vitals trajectory model in a multicenter cohort of patients hospitalized with COVID-19 and to evaluate the clinical characteristics and outcomes of the resulting subphenotypes. RESEARCH QUESTION: Can the trajectory of routine bedside vital signs identify COVID-19 subphenotypes with distinct clinical characteristics and outcomes? STUDY DESIGN AND METHODS: The study included adult patients admitted with COVID-19 to four academic hospitals in the Emory Healthcare system between March 1, 2020, and May 31, 2022. Using a validated group-based trajectory model, we classified patients into previously defined vital sign trajectories using oral temperature, heart rate, respiratory rate, and systolic and diastolic BP measured in the first 8 h of hospitalization. Clinical characteristics, biomarkers, and outcomes were compared between subphenotypes. Heterogeneity of treatment effect to tocilizumab was evaluated. RESULTS: The 7,065 patients with hospitalized COVID-19 were classified into four subphenotypes: group A (n = 1,429, 20%)-high temperature, heart rate, respiratory rate, and hypotensive; group B (1,454, 21%)-high temperature, heart rate, respiratory rate, and hypertensive; group C (2,996, 42%)-low temperature, heart rate, respiratory rate, and normotensive; and group D (1,186, 17%)-low temperature, heart rate, respiratory rate, and hypotensive. Groups A and D had higher ORs of mechanical ventilation, vasopressors, and 30-day inpatient mortality (P < .001). On comparing patients receiving tocilizumab (n = 55) with those who met criteria for tocilizumab but were admitted before its use (n = 461), there was significant heterogeneity of treatment effect across subphenotypes in the association of tocilizumab with 30-day mortality (P = .001). INTERPRETATION: By using bedside vital signs available in even low-resource settings, we found novel subphenotypes associated with distinct manifestations of COVID-19, which could lead to preemptive and targeted treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AdultHumansBiomarkersRespiration, ArtificialHeart RateVital Signs

Stichwörter der Autor:innen

COVID-19phenotypessubphenotypestrajectoryvital signs

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Medicine, Emory University, Atlanta, GA; Emory Critical Care Center, Atlanta, GA. Electronic address: sbhava2@emory.edu.
  • Department of Biomedical Informatics, Emory University, Atlanta, GA.
  • Department of Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI; Hawaii Permanente Medical Group, Honolulu, HI.
  • Department of Medicine, University of Wisconsin, Madison, WI.
  • Emory Critical Care Center, Atlanta, GA; Department of Surgery, Emory University, Atlanta, GA.

Förderung

  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute of General Medical Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Bhavani, S. V., Robichaux, C., Verhoef, P. A., Churpek, M. M., & Coopersmith, C. M. (2024). Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes. CHEST, 165(3), 529-539. https://doi.org/10.1016/j.chest.2023.09.020

Vancouver

Bhavani SV, Robichaux C, Verhoef PA, Churpek MM, Coopersmith CM. Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes. CHEST. 2024;165(3):529-539. doi:10.1016/j.chest.2023.09.020

BibTeX
@article{Bhavani2024,
  author = {Bhavani, Sivasubramanium V and Robichaux, Chad and Verhoef, Philip A and Churpek, Matthew M and Coopersmith, Craig M},
  title = {Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes},
  journal = {CHEST},
  year = {2024},
  volume = {165},
  number = {3},
  pages = {529--539},
  doi = {10.1016/j.chest.2023.09.020}
}
Kostenlos starten →